Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B

Journal of Viral Hepatitis

Volumn 12, Issue 2, 2005, Pages 216-221

  Park, Neung Hwa ^a   Shin, J W ^a   Park, J H ^a   Bang, S J ^a   Kim, D H ^a,a   Joo, K R ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatitis B e antigen seroconversion; Lamivudine; Quantitative hepatitis B e antigen levels; Viral breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 14844325741     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00602.x     Document Type: Article

References (19)

1. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)-and (-)- 2′,3′-dideoxy-3′-thiacytidine as antihepatitis B virus agents. J Biol Chem 1992; 267: 22414-22420.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
3. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose ranging study. Gastroenterology 1997; 339: 1258-1263.
4. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998:339: 61-68.
5. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
6. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117.
7. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.
8. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
9. Song BC, Suh DJ, Lee HJ, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806.
10. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532.
11. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834.
12. Perrillo RP, Minims L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18: 1306-1312.
13. Heijtink RA. Kruining J, Honkoop P et al. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997; 53: 282-287.
14. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Use of quantitative assays for hepatitis Be antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996; 91: 2323-2328.
15. Bernard F, Raymond G, Willems B, Villeneuve J-P. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV-DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997; 4: 265-272.
16. Heijtink RA, Janssen HLA, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000; 7: 382-386.
17. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194.
18. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774.
19. Kirishima T, Okanoue T, Daimon Y et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease B patients before and during lamivudine treatment. J Hepatol 2002; 37: 259-265.